Table 2.

Details of samples including type, country of origin, HIV-1 subtype, prior ARV exposure and estimated viral load of sample source; description of HIV-1 isolates; number of nucleotide mixtures, insertions, and drug resistance mutations in TAQAS 1, 2 and 3.

TAQAS panel—sample	Sample type	Country of origin	HIV-1 Subtype	Estimated HIV RNA load (log10 copies/ml)	ARV drugs to which source has been exposed	No. NMs/insertions per TAQAS	No. DRMS per TAQAS
							Total	Complete	Partial	DRMs as NMs (%)
1-A	P	Australia	B	3.1	d4T, RTV, AZT, 3TC, NFV, SQV, KAL
1-B	P	Australia	B	5.1	3TC, ddI, d4T, T20, SQV, TDF, KAL, RTV, AZT, IDV, NFV, ABV, EFV, AZT
1-C	P	Australia	B	4.0	EFV, d4T, ABV, RTV, CBV, SQV, TPV, TDF, KAL, 3TC, AZT	73	46	35	11	31
1-D	P	Australia	B	4.7	LPV, ABV, NVP, RTV, IDV
1-E	P	Australia	B	5.0	None
2-A	P	Australia	B	5.3	3TC, ddI, d4T, T20, SQV, TDF, KAL, RTV, AZT, IDV, NFV, ABV, EFV, AZT
2-B	P	Australia	B	4.7	None
2-C	P	Australia	B	>4.0	LPV, TDF, 3TC	48	59	48	11	23
2-D	P	Australia	B	>4.0	KAL, 3TC, ABV
2-E	SN	Uganda	D	ND	Not known
3-A	P	Australia	B	4.7	NVP, ddI, ABV, TDF, NFV
3-B	P	Australia	B	4.7	SQV, LPV, ABV, T20
3-C	P	Australia	B	4.7	RTV, SQV, IDV, AZT, 3TC, ddI, d4T, NFV, EFV	109/1	42	23	19	45
3-D	P	Australia	B	4.5	ABV, IDV, CBV, T20, RTV, TPN, 3TC, TDF
3-E	SN	Zimbabwe	C	ND	Not known

P, plasma; SN supernatant for virus co-culture; ND, not done; d4T, stavudine; RTV, ritonavir; AZT, zidovudine; 3TC, lamivudine; NFV, nelfivanir; SQV, saquinavir; KAL, kaletra; ddI, didanosine; T20, enfurviritide; TDF, tenofovir; IDV, indinavir; Abacavir; ABV; EFV, efavirenz; CBV, combivir; TPV, tipranavir; LPV, lopinavir; NVP, nevirapine; NMs, nucleotide mixtures; DRMs, drug resistance mutations.